Swiss pharmaceutical giant Novartis reported robust performance in 2025, buoyed by strong sales. Despite facing stiff competition from generic drugs in the crucial U.S. market, the company managed to maintain a positive trajectory. This success reflects Novartis's ability to navigate a challenging market, driven by its diverse portfolio of innovative medicines.